For diroximel fumarate (VumerityTM), which has been approved for use by health insurers since November 1, 2021, an updated analysis of the phase III EVOLVE-MS-1 study was presented at the ECTRIMS Congress, confirming the benefit-risk profile observed to date1-4. In EVOLVE-MS-2, the direct comparison with dimethyl fumarate (Tecfidera®), diroximel fumarate was characterized by significantly improved tolerability. off5,6. Work under real-world conditions also showed high persistence and adherence in patients on diroximel fumarate, even after prior therapy with dimethyl fumarate7.